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A B S T R A C T   
Background: Metformin, a first-line oral antidiabetic agent that has shown promising results in terms of treating 
childhood and adolescent obesity, might influence the composition of the gut microbiota. We aimed to evaluate 
whether the gut microbiota of non-diabetic children with obesity changes after a metformin intervention. 
Methods: The study was a multicenter and double-blind randomized controlled trial in 160 children with obesity. 
Children were randomly assigned to receive either metformin (1 g/day) or placebo for 6 months in combination 
with healthy lifestyle recommendations in both groups. Then, we conducted a metagenomic analysis in a sub-
sample obtained from 33 children (15 metformin, 18 placebo). A linear mixed-effects model (LMM) was used to 
determine the abundance changes from baseline to six months according to treatment. To analyze the data by 
clusters, a principal component analysis was performed to understand whether lifestyle habits have a different 
influence on the microbiota depending on the treatment group. 
Results: Actinobacteria abundance was higher after placebo treatment compared with metformin. However, the 
interaction time x treatment just showed a trend to be significant (4.6% to 8.1% after placebo vs. 3.8 % to 2.6 % 
after metformin treatment, p = 0.055). At genus level, only the abundance of Bacillus was significantly higher 
after the placebo intervention compared with metformin (2.5% to 5.7% after placebo vs. 1.5 % to 0.8 % after 
metformin treatment, p = 0.044). Furthermore, different ensembles formed by Firmicutes, Bacteroidetes, and 
Verrucomicrobia were found according to the interventions under a similar food consumption. 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FDA, Food and Drug Administration; HDLc, high-density lipoproteins-cholesterol; HFD, high- 
fat-diet; HOMA-IR, homeostasis model assessment for insulin resistance; KMO, Kaiser-Meyer-Olkin; LB, Hospital Clínico Universitario Lozano-Blesa; LDLc, low- 
density lipoproteins-cholesterol; MVPA, moderate-to-vigorous physical activity; QUICKI, quantitative insulin sensitivity check index; RCT, randomized controlled 
trial; RS, Hospital Universitario Reina Sofía; SBP, systolic blood pressure; SENC, Spanish Community Nutrition Society; T2D, type 2 diabetes; US, Hospital Uni-
versitario de Santiago de Compostela; VN, Hospital Universitario Virgen de las Nieves: WC Waist circumference. 
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Conclusion: Further studies with a large sample size controlled by lifestyle patterns are required in obese children 
and adolescents to clarify whether metformin might trigger gut microbiota alterations. Trial Registration: 
Registered on the European Clinical Trials Database (EudraCT, ID: 2010− 023061-21) on 14 November 2011.   
1. Introduction 
Overweight and obesity in children are the most challenging health 
problems in the 21 st century [1]. In this regard, the composition of gut 
microbiota during early life has been suggested to influence the devel-
opment of overweight/obesity in children [2]. Recent evidence suggests 
that gut microbiota is involved in the control of body weight, energy 
homeostasis, and inflammation, playing a role in the pathophysiology of 
obesity [3–6]. 
Metformin (1, 1- dimethyl biguanide) is an oral anti-hyperglycemic 
agent approved by the Food and Drug Administration (FDA) to treat 
type 2 diabetes (T2D) in adults and children older than 10 years of age. 
Beyond its antidiabetic effects, metformin has been considered a 
promising compound for the amelioration of childhood and adolescent 
obesity, especially through the reduction of body mass index (BMI) Z- 
score and waist circumference [7–9]. Interestingly, its absorption is 
limited to around 60 % of the administered dose, and the unabsorbed 
fraction of the drug is excreted unmodified in the feces [10]. Therefore, 
metformin is accumulated in the intestine at very high concentrations 
[11,12], which can lead to potential interaction with microbial com-
munities and possibly it plays a role against obesity and its metabolic 
complications [13]. Hence, recent literature suggests that metformin 
action may be predominantly mediated via the gut [10,14]. Supporting 
this idea, studies in obese animal models [15,16] or with high-fat-diet 
(HFD) [13] show that gut microbiota and their metabolic pathways 
are altered by metformin treatment. Specifically, metformin enhances 
the abundance of Akkermansia muciniphila in obese animal models [13, 
15,17] and decreases amounts of the bacteria which have been linked to 
the development of obesity, insulin resistance, and diabetes [18]. In 
humans, while several studies have investigated the effect of metformin 
on gut microbiota composition in diabetic subjects [19–23], only one 
has been focused on obese subjects [24]. Global gut microbial diversity 
indices were unaffected in obese women with a low-calorie diet after the 
metformin treatment. However, the authors observed an increase in 
Escherichia/Shigella abundance in the metformin-treated obese women, 
but Akkermansia did not change significantly. In obese children, the 
composition of gut microbiota after metformin intervention has not 
been studied. Furthermore, there is a lack of knowledge about how 
eating patterns in children with obesity are related to intestinal micro-
biota when they are undergoing an intervention with metformin. Pre-
viously, we conducted a randomized control trial (RCT) in 160 children 
with obesity and demonstrated that a 6-month intervention with 
1 g/day of metformin and lifestyle recommendations decreases the BMI 
Z-score and improves inflammatory and cardiovascular-related obesity 
parameters [8]. Stomach pain and diarrhea were the most common 
adverse effects reported in our study, comprising 18.8 % and 13 % of the 
cases, respectively. Therefore, we pretend 1) to investigate the alteration 
of the gut microbiota in 33 children with obesity after metformin 
intervention in comparison with a placebo group, and 2) to assess the 
relationships between lifestyle characteristics and gut microbiota, 
highlighting the potential impact of dietary and physical activity pat-
terns on microbiome of children with obesity. 
2. Methods 
2.1. Study design, participants and intervention 
The study was a multicenter and double-blind RCT, stratified ac-
cording to sex and pubertal status in 160 non-diabetic children with 
obesity. The pubertal stage was determined according to Tanner criteria 
[25] and obesity defined according to BMI by using the age- and 
sex-specific cut-off points proposed by Cole et al. (BMI greater than the 
95th percentile) [26]. All the children were randomly assigned to 
receive 1 g/day of metformin or placebo for 6 months after meeting the 
defined inclusion criteria [8,27]. Both experimental groups included a 
lifestyle recommendation program. Further details regarding study 
protocol [27], informed consent and ethics, design, sample size, inter-
vention and participants (participant’s data collection and processing, 
samples codification, randomization method, double-blind condition, 
and side effects assessment) have been previously described [8,27]. The 
CONSORT statement (Consolidated Standards of Reporting Trials) has 
been considered in the study design report and the abstract. The study 
was registered by the European Clinical Trials Database (EudraCT, ID: 
2010− 023061-21) on 14 November 2011 (URL: https://www.clinical-
trialsregister.eu/ctrsearch/search?query=2010− 023061-21). 
2.2. Anthropometric and biochemical measurements 
The procedure for the collection of the data concerning anthro-
pometry, blood pressure, and the biochemical parameters measured in 
the current study have been previously reported [8,27]. The Quantita-
tive Insulin Sensitivity Check Index (QUICKI) and the homeostasis 
model assessment for insulin resistance (HOMA-IR) were calculated 
using the fasting plasma glucose and insulin values: fasting insulin 
(μU/L) x fasting glucose (nmol/L)/22.5 and 1 / (log(fasting insulin) +
log(fasting glucose)), respectively. 
2.3. Metagenomic analysis 
For the metagenomic analysis, a subsample was obtained from 63 
children, which both they and their parents/guardians agreed with 
collecting the stools. Each volunteer provided fecal samples 
(100− 200 g), both at the beginning and the end of the trial. The fecal 
samples were collected in a hermetically sealed, sterile container pro-
vided by the Pediatric Endocrinology Unit of the corresponding study 
centers. Samples were immediately refrigerated in household freezers 
and brought in a small fridge with patch of ice to corresponding hospital 
within 12 h after collection and then transferred to − 80 ◦C until they 
were used for the analysis. The reception of samples occurred exclu-
sively in the morning (8.30–10.30 a.m.). However, we selected those 
children with stool samples both at the beginning and at the end of the 
intervention (n = 33 paired samples: 15 metformin, 18 placebo). 
Figure S1 describes all the steps for the metagenomics analysis. 
2.3.1. DNA extraction 
Samples were homogenized in a Stomacher-400 blender. Subse-
quently, a QIAamp DNA Stool Mini Kit (QIAGEN, Barcelona, Spain) was 
used for the DNA extraction as indicated by the manufacturer with the 
exception of the incubation at 70 ◦C, since the samples were mixed with 
the lysis buffer and incubated at a temperature of 95 ◦C to make sure 
that both Gram-positive and Gram-negative were lysed. The quantifi-
cation of the DNA was conducted with a NanoDrop ND1000 spectro-
photometer (Thermo Fisher Scientific, DE, USA) and the DNA yield was 
calculated by measuring absorbance ratios spectrophotometrically, 
including A260/230 nm for salt and phenol contamination and A260/ 
280 nm for protein contamination [28]. 
2.3.2. Sequencing and taxonomic analysis 
The amplification of the extracted DNA was done through PCR using 
the primer pairs, 16S Amplicon PCR forward primer: 
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5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNG-
GCWGCAG, and 16S Amplicon PCR Reverse Primer: 
5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHV 
GGGTATCTAATCC targeting the V3 and V4 hypervariable regions of the 
bacterial 16S rRNA gene [29]. Every single PCR was performed in 25 μL 
reaction volumes of which 12.5 μL was 2X KAPA HiFi Hotstart ready mix 
(KAPA Biosystems, Woburn, MA, USA). The rest corresponded to 5 μL of 
each forward and reverse primers (1 μM) and 2.5 μL of extracted DNA 
(10 ng). The cycling conditions were also the same for each PCR: initial 
denaturation at 95 ◦C for 3 min, followed by cycles of denaturation at 
95 ◦C for 30 s, annealing at 55 ◦C for 30 s, and elongation at 72 ◦C for 
30 s, with a final extension at 72 ◦C for 5 min. AMPure XP beads 
(Beckman Coulter, Indianapolis, IN, USA) were used for the PCR 
clean-up to purify the 16S V3 and V4 amplicon away from free primers 
and primer-dimer species. After this, the index PCR was performed 
under 95 ◦C for 3 min; 8 cycles of 95 ◦C for 30 s, 55 ◦C for 30 s, 72 ◦C for 
30 138 s; 72 ◦C for 5 min, and hold at 4 ◦C, using the Nextera XT Index 
Kit (Illumina, San Diego, CA, USA) to attach dual indices and Illumina 
sequencing adapters. Then, before the quantification, the pooled PCR 
products were purified using AMPure XP beads (Beckman Coulter, 
Indianapolis, IN, USA). The resultant amplicons were sequenced at 
MiSeq (Illumina, USA), using paired-end (2 × 300nt) Illumina MiSeq 
sequencing system (Illumina, San Diego, CA, USA) [28]. 
Microbial community diversity was analyzed. Hence, diversity (H), 
Simpson index, inverse Simpson index, Alpha index (Fisher), species 
richness, Pielou’s evenness index, and beta diversity indexes were 
calculated with Vegan v.2.4− 2 in R package with the option ecological 
diversity indices at the phylum level (Table S1) [29]. The observed 
relative abundance of each taxon was estimated by counting the number 
of reads for each taxon and then this was normalized by the total number 
of reads per sample. The phyla and genera represented in this study were 
those with a relative abundance higher than ≥ 0.1 %. However, based on 
the literature in relation to a possible effect of metformin on enhancing 
the abundance of A. muciniphila in obese animal models [13,17,30], its 
genus, Verrucomicrobia, was included although the abundance was < 0.1 
%. 
Negative controls from laboratory reagents were processed in par-
allel with the samples to assess for possible microbial contamination. 
2.4. Lifestyle monitoring 
The dietitians at the centers applied a food frequency questionnaire 
and a physical activity survey to all subjects at the beginning and at the 
end of the study, both of them validated and normalized [31]. The food 
groups were classified as 1) Cereals, pasta and legumes, 2) Vegetables, 3) 
Fruits and fresh fruit juices, 4) Olive oil, 5) Milk products, 6) Fish, 7) 
Eggs and white meat, 8) Fat meat and processed cold-meat, 9) Sweets, 
snacks and soft drinks, 10) Butter, cakes and pastry. Thereupon, the 
Spanish Community Nutrition Society (SENC) Guidelines for scholar age 
were used to compare the food habits of the studied children with the 
standard recommendations [32]. For sedentary habits, we grouped the 
following data to create the “screen time” variable (measured as 2 h/day 
in front of the screen): “How much time does your child spend for 
watching TV, video or DVD”, “How much time does your child spend in 
front of the computer (for internet, video games…)”, How much time 
does your child spend using the game console?”, “How much time does 
your child spend on using the mobile phone?”. Furthermore, to obtain 
the minutes/day of moderate-to-vigorous physical activity (MVPA), we 
used the data based on the following questions: “How many hours per 
day do you practice sports with moderate efforts (running, sky, dancing, 
ball games, swimming…)”, How many hours per day do you practice 
sports with vigorous efforts (sport training)?”. 
Moreover, the data collected in the lifestyle habits questionnaire 
were evaluated according to the healthy lifestyle-diet index (HLD-index) 
described by Manios et al. to ensure a routine quality estimation. The 
total score on the HLD-index ranges from 0 to 48 [33]. Higher scores on 
the HLD-index indicate greater adherence to dietary–lifestyle recom-
mendations or to a ‘healthy’ dietary–lifestyle pattern. Based on this 
scoring, Manios et al. considered three groups by tertiles of the 
HLD-index: unhealthy lifestyle-diet pattern = ranging from 1 to 16; 
moderately healthy lifestyle-diet pattern = ranging from 17 to 32; and 
healthy lifestyle-diet pattern = ranging from 33 to 48. 
2.5. Statistical analysis 
Data are given as the mean and standard mean error (SEM). P < 0.05 
was considered to be statistically significant. Variables that were not 
normally distributed were log-transformed for analysis, and/or values 
with ± 3SD of the mean (outliers) were removed (without achieving 
values loss from samples of up to 15 %). However, the data are presented 
as untransformed values to ensure a clear understanding. For the clinical 
characteristics of the participants, differences at baseline and post- 
treatment per experimental group were assessed by using Student t- 
test or U Mann-Whitney test when variables showed a no normal dis-
tribution. For the relative abundances of bacteria (phylum and genus), U 
Mann-Whitney test was applied for assessing differences at baseline, as 
well as for the alpha indexes and beta diversity (Table S1). ANCOVA was 
used at the post-treatment stage when differences at baseline in the 
clinical characteristics were observed between experimental groups. For 
categorical variables (sex, pubertal stage, center, screen time, food fre-
quency and gastrointestinal side effects), the χ2 test was applied. 
A linear mixed-effects model (LMM) was used to determine the 
abundance changes from baseline to six months according to treatment. 
The specific differences between the treatments were assessed by post 
hoc Bonferroni tests. The fixed effects included in all the models were 
sex, pubertal stage, and adherence to the treatment (% based on the 
following formula: ((Pills ingested – pills returned) / Pills predicted) x 
100) and the time x treatment interaction, while subject and center were 
included as random effects. The normality of residuals was checked for 
all the models and Q–Q plots are available upon request. To analyze the 
data by clusters, a principal component analysis was performed to un-
derstand whether lifestyle habits have a different influence on the 
microbiota depending on the intervention group, maximizing the in-
formation gained for the predominant bacterial variables. We have 
mixed here bacterial variables and alimentary groups obtained from 
food frequency questionnaire and some lifestyle habits such as screen 
time and MVPA. This mathematical model calculates new variables 
(principal components) that account for the variability in the meta-
genomic data and enables the study of covariance or correlations be-
tween variables (e.g., eggs and white meat (portions/week), fruit and 
fresh juices (portions/day), among others). The combination of diet and 
physical activity variables with the greatest amount of variability is the 
first principal component. The subsequent components (second and 
third principal components) describe the maximum amount of remain-
ing variability [34]. All of the analyses were performed using SPSS 
software version 24 (SPSS Inc., Chicago, IL, USA). 
3. Results 
The general and clinical characteristics of the children at baseline 
and after 6 months for each intervention group are reported in Table 1. 
Differences in the prevalence of gastrointestinal side effects were not 
observed. Differences in the food frequency were not observed per 
treatment (p > 0.05), except the fish intake at baseline (p = 0.025) 
(these data are not presented here, but are available upon request). In 
bacteria, it did not show any significant differences at baseline 
(p > 0.05) and consequently these are not presented here, but are 
available upon request. 
Tables 2 and 3 show the relative abundances of predominant phyla 
and genera in the studied children, respectively. Reads were classified 
into more than 4000 different taxons. All samples were rarefied to 
prevent bias due to sampling depth. At the phylum level, the relative 
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abundance was not different by treatment at the end of the study 
(Table 2). Actinobacteria was higher after placebo treatment compared 
with metformin. However, the interaction time x treatment just showed a 
trend to be significant (p = 0.055) (Table 2). At the genus level, only the 
abundance of Bacillus was significantly higher after the placebo inter-
vention compared with metformin (p = 0.044) (Table 3). 
Principal component analyses were performed with bacteria and 
lifestyle variables, according to alimentary groups with portions per day 
or per week, and screen time and MVPA as the variables of sedentary 
habits and physical activity, respectively. The variables that were finally 
maintained in the principal component analyses (Fig. 1) were selected 
according to the Kaiser-Meyer-Olkin (KMO) (p > 0.05), to warrant 
sampling adequacy for each analysis [34]. 
In placebo group, component one was defined by the consumption of 
fish, butter, cakes, pastry and Bacteroidetes that were correlated 
inversely with the consumption of milk products, Firmicutes and Verru-
comicrobia (Fig. 1. A). Component two was defined by the consumption 
of butter, cakes and pastry, eggs and white meat and vegetables that 
were negatively correlated with MVPA. Finally, component three has 
shown Verrucomicrobia and fruits and fresh juices consumption corre-
lated negatively with butter, cakes and pastry and fatty meat and pro-
cessed cold-meat. In children that received metformin, component one 
was defined by the consumption of fatty meat and processed cold-meat, 
Firmicutes and MVPA that were correlated inversely with Bacteroidetes 
and consumption of vegetables (Fig. 1B). Fruits and fresh juices, fish and 
eggs and white meat consumption established component two and were 
Table 1 
Clinical characteristics of the study population at baseline and post-treatment stages.   
Baseline 6 months  
Placebo Metformin P-value a Placebo Metformin P-value a   
n = 15  n = 18 n = 15  
Adherence (%)b – – – 88.8 (3.9) 93.9 (3.1) 0.078 
Sex (Females, %) 33.3 60 0.126 – – – 
Pubertal stage (Prepubertal, %) 22.2 13.3 0.510 – – – 
Centre (RS/VN/US/LB) 11.1/22.2/33.3/33.3 0/20/20/60 0.321 – – – 
Screen time (> 2 h/d) (%) 33.3 33.3 1 33.3 46.7 0.219 
MVPA (min/d)b 63.1 (17.9) 87.6 (17.6) 0.073 22.5 (7.03) 19.4 (3.09) 0.393 
Age (y) 12 (0.6) 12 (0.4) 0.955 12.5 (0.6) 12.8 (0.3) 0.624 
Abdominal pain (yes, %) – – – 11.1 26.7 0.239 
Diarrhea (yes, %) – – – 5.6 20 0.178 
BMI Z-score 3.5 (0.2) 2.8 (0.2) 0.034 3.05 (0.19) 2.38 (0.25) 0.433c 
WC (cm) 97.2 (3) 90.3 (2.9) 0.110 95.2 (2.7) 89.5 (2.2) 0.139 
Fat mass (%) 36.8 (1.3) 37.2 (1.2) 0.853 34.7 (1.5) 35.6 (1.3) 0.656 
Lean mass (%) 60 (1.9) 52.3 (3) 0.032 64.7 (2.3) 67.8 (3.8) 0.272c 
DBP (mmHg) 69.2 (2.2) 68.2 (1.9) 0.736 68.3 (2.3) 65.7 (2.5) 0.448 
SBP (mmHg) 116.7 (3.2) 115.8 (2.8) 0.844 115.9 (2.8) 111.6 (3.5) 0.343 
Fasting glucose (mg/dL) 83.7 (1.5) 87.5 (1.5) 0.082 84.1 (1.4) 84.7 (2.2) 0.793 
Fasting insulin (μU/mL) 22.5 (2.9) 23.4 (2.6) 0.809 20.4 (1.8) 22.2 (3.2) 0.593 
HOMA-IR index 4.8 (0.6) 5.1 (0.6) 0.712 4.2 (0.4) 4.6 (0.6) 0.622 
QUICKI indexb 0.3 (0.03) 0.3 (0.02) 0.516 0.3 (0.02) 0.3 (0.03) 0.729 
Total cholesterol (mg/dl) 156.6 (6) 155.1 (6.2) 0.865 154.1 (7.3) 154.1 (5.3) 0.997 
TG (mg/dl) 20.4 (1.8) 22.2 (3.2) 0.433 73.4 (7.6) 85.8 (13.9) 0.465 
HDLc (mg/dl) 45.8 (2.5) 49.8 (2.4) 0.269 45.7 (2.6) 53.3 (3.2) 0.073 
LDLc (mg/dl) 96.4 (5.9) 88.9 (4.6) 0.336 92.3 (6.7) 84.3 (4.8) 0.368 
Data are expressed as mean (standard error of mean) for continuous variables or n for categorical variables. 
a)Differences between experimental groups at baseline and post-treatment were analyzed using the Student t-test or U Mann-Whitney test (marked as b) for quantitative 
variables, or ANCOVA (marked as c) when differences at baseline were observed between experimental groups. χ2 test was used for categorical variables. P-value <
0.05 marked in bold. Abbreviations: BMI, body mass index, DBP, diastolic blood pressure, HDLc, high-density lipoproteins-cholesterol, HOMA-IR, homeostasis model 
assessment for insulin resistance, LB, Hospital Clínico Universitario Lozano-Blesa, LDLc, low-density lipoproteins-cholesterol, MVPA, moderate-to-vigorous physical 
activity, QUICKI, quantitative insulin sensitivity check index, RS, Hospital Universitario Reina Sofía, SBP, systolic blood pressure, US, Hospital Universitario de 
Santiago de Compostela, VN, Hospital Universitario Virgen de las Nieves, WC, Waist circumference. 
Table 2 
Relative abundances of bacteria in fecal microbiota of studied children at the phylum level.  
Bacterial variables Placebo Metformin P-value 
a 
Phylum Baseline (n = 18) 6 months (n = 18) Baseline (n = 15) 6 months (n = 15)  
Actinobacteria 4.6 (1.3) 8.1 (1.5) 3.8 (1.5) 2.6 (1.6) 0.055 
Bacteroidetes 34.1 (4.1) 28.1 (4.5) 32.4 (5.2) 38.8 (5.6) 0.125 
Firmicutes 49.1 (3.6) 50.4 (3.8) 49.3 (4.6) 46.6 (4.8) 0.455 
Proteobacteria 0.4 (0.1) 0.6 (0.1) 0.6 (0.2) 0.6 (0.2) 0.660 









Alpha diversity 39.5 (18–78) 45.5 (11–68) 37 (5–74) 42 (21–56)  
Unclassified sequences derived from 
bacteria 
4.4 (1.0–16.2) 4.9 (0.7–33.5) 5.2 (1.4–50.9) 7.2 (0.8–18.6)  
Phylum abundance is expressed as mean adjusted (standard error of mean). A linear mixed-effects model (LMM) was used to determine the abundance changes from 
baseline to six months according to treatment. The specific differences between the treatments were assessed by post hoc Bonferroni tests. The fixed effects included in 
all the models were sex, pubertal stage, and adherence to the treatment (% based on the following formula: ((Pills ingested – pills returned) / Pills predicted) x 100) and 
the time x treatment interaction, while subject and center were included as random effects. a P-value for the time x treatment interaction. Table 2 shows only the phylum 
abundances with a value ≥ 0.1 %. 
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negatively correlated with Verrucomicrobia and MVPA. Finally, compo-
nent three was defined with the positive correlation between the con-
sumption of milk products, butter, cakes and pastry and MVPA 
correlated inversely with fish consumption and Verrucomicrobia. 
4. Discussion 
The current study evaluates the fecal microbiota in children with 
obesity after a metformin intervention vs. another based-on placebo, 
both with lifestyle recommendations. 
Although the time x treatment interaction was not significant, we 
observed an interesting change in the Actinobacteria abundance from 4.6 
to 8.1% after placebo treatment, in comparison with metformin which 
decreased from 3.8 to 2.6 %. Furthermore, the abundance of Bacillus 
species increased significantly from 2.5 to 5.7 % in placebo compared 
with metformin group, that showed a slight reduction from 1.5 to 0.8 %. 
It is known that obesity contributes to disturb microbial diversity [35]. 
Concretely, both the abundance of Actinobacteria and Bacillus are 
increased in obesity status [36–39]. In this context, metformin might 
slightly attenuate the increment of them in children with obesity, 
although further evidence is needed to elucidate the effect of metformin 
on Actinobacteria abundance on this population. Recently, a study 
showed that the increased abundance of Actinobacteria observed in T2D 
mice decreased in the group treated with metformin [40]. Dietary and 
physical activity patterns have important effects on the microbiota [18, 
41]. Moreover, in rodents, metformin has been shown to modify gut 
microbiota composition and diversity, but in a diet-dependent manner 
[2526 genes]. Actually, Shin et al. [25] showed that there are significant 
differences in the abundance of Firmicutes and Bacteroidetes, between 
metformin-treated and non-treated mice, but only under a HFD. Simi-
larly, Lee and Ko [26] observed that metformin induces a decrease in 
bacterial diversity in mice under a HFD. Thus, we considered to take a 
further step and to analyze jointly the lifestyle and the gut microbiota in 
each intervention group. When data about lifestyle were introduced as 
Table 3 
Relative abundances of bacteria in fecal microbiota of studied children at the genus level.  
Bacterial variables Placebo Metformin P-value a 
Genus Baseline (n = 18) 6 months (n = 18) Baseline (n = 15) 6 months (n = 15)  
Acetivibrio 1.8 (0.3) 1.6 (0.3) 1.9 (0.4) 2.1 (0.4) 0.543 
Acidaminococcus 1.3 (0.6) 1.1 (0.6) 1.6 (0.7) 1.7 (0.8) 0.803 
Agreia 3.3 (1.5) 3.2 (1.7) 5.8 (2) 4.7 (2.1) 0.775 
Akkermansia 0.011 (0.009) 0.008 (0.010) 0.007 (0.011) 0.021 (0.012) 0.378 
Alicycliphilus 4.5 (1.1) 2.6 (1.2) 5.4 (1.4) 5.6 (1.5) 0.319 
Avibacterium 0.9 (0.3) 0.6 (0.4) 1.1 (0.4) 1.2 (0.5) 0.603 
Bacillus 2.5 (1) 5.7 (1) 1.5 (1.2) 0.8 (1.3) 0.044 
Bavariicoccus 0.7 (0.2) 1.3 (0.2) 0.8 (0.2) 0.7 (0.2) 0.061 
Bradyrhizobium 1.2 (0.4) 2.1 (0.5) 0.7 (0.5) 1.5 (0.6) 0.937 
Chlamydia 2 (0.6) 2.4 (0.7) 2.2 (0.8) 1.5 (0.8) 0.395 
Desulfosalina 4.1 (0.7) 4.7 (0.7) 3.8 (0.8) 3.6 (0.9) 0.532 
Desulfotomaculum 12.1 (1.8) 11.2 (2) 9.7 (2.2) 7.5 (2.4) 0.678 
Flexibacter 0.3 (0.1) 0.4 (0.1) 0.4 (0.1) 0.4 (0.2) 0.51 
Marinilabilia 0.4 (0.1) 0.2 (0.1) 0.5 (0.1) 0.4 (0.1) 0.748 
Nautilia 6.4 (3.5) 7.4 (3.6) 7.3 (4.3) 9.1 (4.4) 0.825 
Oscillochloris 0.5 (0.2) 0.6 (0.2) 0.7 (0.3) 0.5 (0.3) 0.554 
Oxalobacter 2.9 (0.7) 4.8 (0.8) 2.1 (0.9) 2.9 (1) 0.435 
Paraprevotella 3.9 (0.7) 5.2 (0.7) 4.5 (0.9) 5.4 (0.9) 0.754 
Stackebrandtia 5.2 (2.2) 8.4 (2.3) 7.5 (2.8) 7.5 (2.9) 0.275 
Streptococcus 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.1 (0.1) 0.137 
Veillonella 0.4 (0.1) 0.4 (0.1) 0.2 (0.1) 0.3 (0.1) 0.988 
Phylum abundance is expressed as mean (standard error of mean). A linear mixed-effects model (LMM) was used to determine the abundance 
changes from baseline to six months according to treatment. The specific differences between the treatments were assessed by post hoc Bonferroni 
tests. The fixed effects included in all the models were sex, pubertal stage, and adherence to the treatment (% based on the following formula: 
((Pills ingested – pills returned) / Pills predicted) x 100) and the time x treatment interaction, while subject and center were included as random 
effects. a P-value for the time x treatment interaction. P-values < 0.05 marked in bold. Table 3 shows only the genus abundances with a value ≥ 0.1 %. 
Fig. 1. Principal component analysis between intestinal microbiota and lifestyle variables in children treated with metformin and placebo after 6 months of the 
intervention. Strong loading was defined as a value < 0.6, moderate as 0.3-0.59 and low as <0.3. KMO, Kaiser-Mayer-Olkin. a) Placebo group, b) Metformin group. 
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variables to build principal components with the fecal microbiota, we 
detected interesting predominant variables grouped differently accord-
ing to the interventions despite both treatment groups had a similar food 
intake. Here, although Bacteroidetes, Firmicutes and Verrucomicrobia 
were the phyla that finally constituted the principal components in both 
experimental groups, the correlations with lifestyle variables within the 
components and the importance of them differed by groups. For 
instance, Verrucomicrobia composed the components one and three in 
placebo at the end of the intervention, whereas in the metformin group 
was presented in components two and three with similar loadings, but 
its correlations showed opposed directions with the lifestyle variables 
(Fig. 1A and B); fish, butter, cakes and pastry, and fatty meat and pro-
cessed cold-meat consumption in the placebo group, and fruits and fresh 
juices, fish, eggs and white meat, milk products and butter, cakes and 
pastry in the metformin group. Bacteroidetes and Firmicutes were located 
in the same component at the end of the intervention in both groups 
(Fig. 1A and B), whereas the lifestyle patterns in component one were 
differently expressed by treatment. According to our data in the placebo 
group, several genera belonging to phylum Bacteroidetes were negatively 
associated with milk products, concretely yoghurt intake, in a study with 
younger children [42] and with young adults [43]. Furthermore, Ver-
rucomicrobia constituted component one in the placebo group compared 
with the metformin. Our results have shown that Verrucomicrobia is 
more correlated with the placebo group in opposite with data previously 
published [13] in which this phylum was significantly increased in the 
obese mice treated with metformin. 
To the best of our knowledge, this is the first study that analyses the 
gut microbiota in children with obesity after metformin treatment. As 
the effect of metformin on gut microbiota composition seems to differ 
under healthy and diabetes status [44,45], this could also occur in 
obesity conditions. To date, only one study in obese subjects has been 
performed to evaluate the effect of metformin (in addition to low-calorie 
diet) on the gut microbiota [24]. The authors reported no significant 
changes in the overall fecal microbial composition and diversity. How-
ever, we have to consider that the population studied was adult women 
and it is known that sex and age are important factors that influence gut 
microbiota [46,47]. Furthermore, as a decreased abundance of 
A. muciniphila has been associated with the presence of T2D [17], this 
bacteria is proposed to be a biomarker for glucose intolerance [48]. 
Moreover, it has also been inversely associated with several metabolic 
complications in humans [49–51]. Akkermansia is the main genus re-
ported as increased after metformin treatment in diabetic mice and 
humans [17,19], and it is suggested as a possible mechanism of action to 
exert the antidiabetic effects [17]. However, to date, any study in 
non-diabetic obese subjects treated with metformin has proposed that 
A. muciniphila could be increased using metformin in obese or healthy 
populations [24,52]. Indeed, de la Cuesta-Zuluaga et al. observed an 
increment of the relative abundance of A. muciniphila after taking met-
formin, in participants with T2D, but not in those without T2D [19]. The 
no-effect of metformin on this specie in our subjects could be explained 
due to the no alteration of Akkermansia in the gut microbiota. Unfor-
tunately, we have not a control group based on healthy children to 
compare the abundance of Akkermansia. 
Evidence that abnormalities in the microbiota composition can have 
a major role in the development of obesity and diabetes is constantly 
growing, and also that metformin may mediate its action by gut bacteria 
[53]. Nevertheless, the evidence is still fairly scarce in the young pop-
ulation and nothing has been reported in terms of obesity in children and 
adolescents. One of the major concerns is that obese children are highly 
prone to becoming obese adults and developing severe co-morbidities 
such as metabolic syndrome, T2D and cardiovascular disease [54]. For 
these reasons, the prevention and management of obesity must begin 
before the adult stage. Unfortunately, single-strategy lifestyle interven-
tion is not always effective [55]. Indeed, we previously observed a 
reduction of BMI Z-score in the current study, but the results were much 
more promising in the metformin arm of prepubertal children after the 6 
months of the intervention [8]. 
A limitation of the current study was the reduced sample size for the 
metagenomic analysis due to the low level of involvement from the 
subjects or their parents/guardians to bring the fecal samples. The 
limited sample size also hampered that we could achieve a greater 
number of variables included, such as the bacterial genera, for the 
component analyses. Furthermore, the single nutrient intake collected 
by 24 -h recalls might have provided more information in relation to the 
specific nutrients supplied by the participant’s diet. However, this study 
provides the first data regarding metformin and gut microbiota in obese 
children that might encourage to increase the evidence on this relevant 
issue by further metagenomic studies with greater sample size. We 
highlight the importance to perform future longer term RCTs with a 
large sample size that enable an appropriate stratification by pubertal 
stage to investigate possible and interesting links between the benefits 
demonstrated by metformin along with a healthy lifestyle in terms of 
weight loss and metabolic complications and the alteration of gut 
microbiota. Indeed, the role of metformin on gut microbiota is rising as 
relevant research focus to elucidate novel mechanisms for its thera-
peutic effect. 
5. Conclusions 
Actinobacteria showed to be higher, but not significantly, after pla-
cebo treatment compared with metformin. At the genus level, only the 
abundance of Bacillus was significantly higher after the placebo inter-
vention compared with metformin. These findings could contribute to 
explain a possible attenuation in the increment of these bacteria by 
metformin in children with obesity. Moreover, different ensembles of 
predominant variables were found according to the interventions, under 
a similar food consumption. Here, Firmicutes, Bacteroidetes, and Verru-
comicrobia characterized different patterns along with specific food 
groups. Further studies with a large sample size controlled by lifestyle 
patterns are needed in obese children and adolescents to clarify the 
possible alterations that metformin might trigger in gut microbiota. 
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[14] F.A. Duca, C.D. Côté, B.A. Rasmussen, M. Zadeh-Tahmasebi, G.A. Rutter, B. 
M. Filippi, T.K.T. Lam, Metformin activates a duodenal Ampk-dependent pathway 
to lower hepatic glucose production in rats, Nat. Med. 21 (2015) 506–511, https:// 
doi.org/10.1038/nm.3787. 
[15] H. Lee, Y. Lee, J. Kim, J. An, S. Lee, H. Kong, Y. Song, C.K. Lee, K. Kim, Modulation 
of the gut microbiota by metformin improves metabolic profiles in aged obese 
mice, Gut Microbes 9 (2018) 155–165, https://doi.org/10.1080/ 
19490976.2017.1405209. 
[16] Q. Li, R. He, F. Zhang, J. Zhang, S. Lian, H. Liu, Combination of Oligofructose and 
Metformin Alters the Gut Microbiota and Improves Metabolic Profiles, 
Contributing to the Potentiated Therapeutic Effects on Diet-Induced Obese 
Animals, Front. Endocrinol. (Lausanne). 10 (2020) 939, https://doi.org/10.3389/ 
fendo.2019.00939. 
[17] N. Shin, J.-C. Lee, H.-Y. Lee, M. Kim, T.W. Whon, M. Lee, J. Bae, An increase in the 
Akkermansia spp. Population induced by metformin treatment improves glucose 
homeostasis in diet-induced obese mice, Gut 63 (2014) 727–735, https://doi.org/ 
10.1136/gutjnl-2012-303839. 
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